You just read:

Phoenix Molecular Designs Receives FDA Clearance to Begin Phase 1/1b Clinical Trial with PMD-026, a First-in-Class RSK Inhibitor, Targeting Advanced Breast Cancer

News provided by

Phoenix Molecular Designs

Sep 23, 2019, 08:00 ET